Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Life Sciences
Inducing Dna-Mismatch Repair Deficiency In Tumours: A Strategy To Enhance Anti-Tumour Immunity, Mikal El-Hajjar
Inducing Dna-Mismatch Repair Deficiency In Tumours: A Strategy To Enhance Anti-Tumour Immunity, Mikal El-Hajjar
Electronic Thesis and Dissertation Repository
Immunotherapy has improved patient outcomes in advanced or metastatic settings across a number of cancers. Patients with tumours deficient in the DNA mismatch repair (DNA-MMR) pathway often show high response rates to immune checkpoint inhibitors (ICIs) with a rise in immune surveillance. However, little is known about the immune sensitization effects of inducing DNA- MMR-deficiency in low tumour mutational burden (TMB) cancers, such as ICI refractory neuroblastoma. In addition, the dynamic T-cell profile that results from such a DNA-MMR inactivation, and whether this may confer a therapeutic benefit, is poorly understood. Here we used CRISPR/CAS9 genome editing technology to knock …
Exploiting The Immunomodulatory Potentials Of Inkt Cells In Sepsis And Cancer., Joshua Choi
Exploiting The Immunomodulatory Potentials Of Inkt Cells In Sepsis And Cancer., Joshua Choi
Electronic Thesis and Dissertation Repository
Invariant natural killer T (iNKT) cells are a unique unconventional T cell subset that recognize glycolipids presented by CD1d expressing cells. The prototypical glycolipid agonist of iNKT cells, α-Galactosylceramide (α-GalCer), can induce the rapid release of an arsenal of cytotoxic effector molecules and enormous amounts of immunomodulatory cytokines as early as two hours after activation. In addition to α-GalCer, various glycolipid agonists are available that allow for specific, in vivo targeting of iNKT cells, and can exert divergent T-helper (TH)1 and/or TH2 immune responses. Therefore, the type of response instigated by iNKT cells can profoundly influence …